Skip to main content

Table 2 Clinical characteristics of men with favorable risk PCa in OBS vs IMT cohorts

From: Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study

 

OBS

IMT

  

(n = 362)

(n = 1063)

  

N

%

N

%

p-value

Standardized difference a

Comorbid Indices (CCI)

 0

225

62.2%

750

70.6%

<.01

17.83

 1

59

16.3%

183

17.2%

0.69

2.45

 2+

78

21.6%

130

12.2%

<.01

25.04

Comorbid Conditions

 Hypertension

153

42.3%

405

38.1%

0.16

8.50

 Diabetes

61

16.9%

134

12.6%

0.04

11.99

 COPD

43

11.9%

82

7.7%

0.02

14.03

 Congestive Heart Failure

13

3.6%

27

2.5%

0.30

6.09

 Dementia

0

0.0%

3

0.3%

0.31

7.52

 Benign Prostatic Hyperplasia

130

35.9%

388

36.5%

0.84

1.22

Body Mass Index

 Underweight (< 18.5)

1

0.3%

5

0.5%

0.62

3.18

 Normal (18.5–24.9)

42

11.6%

102

9.6%

0.27

6.52

 Overweight (25.0–29.9)

118

32.6%

342

32.2%

0.88

0.90

 Obese (≥30)

112

30.9%

336

31.6%

0.81

1.44

 Unknown

89

24.6%

278

26.2%

0.56

3.60

Family History of Prostate Cancer

 Yes

74

20.4%

262

24.7%

0.10

10.07

 No

208

57.5%

598

56.3%

0.69

2.43

 Unknown

80

22.1%

203

19.1%

0.22

7.42

 Family History of Cancer

109

30.1%

339

31.9%

0.53

3.85

Prostate Cancer Characteristics

 Index PSA (Mean, SD)

5.8

2.5

5.7

2.5

0.31

6.31

  < 4 ng/mL

69

19.1%

208

19.6%

0.83

1.28

 4–10 ng/mL

256

70.7%

758

71.3%

0.83

1.30

  > 10 ng/mL

30

8.3%

77

7.2%

0.52

3.90

 Unknown

7

1.9%

20

1.9%

0.95

0.38

Index Clinical Stage b

 Stage 1

303

83.7%

855

80.4%

0.17

8.52

 Stage 2

55

15.2%

184

17.3%

0.35

5.73

 Unknown

4

1.1%

24

2.3%

0.17

8.97

 Index Total Gleason Score = 3 + 4

83

22.9%

377

35.5%

<.01

27.82

Risk Category c

 Low-risk

236

65.2%

585

55.0%

<.01

20.84

 Intermediate-risk

117

32.3%

461

43.4%

<.01

22.91

 Unknown

9

2.5%

17

1.6%

0.28

6.27

  1. OBS observation, IMT immediate treatment, SD standard deviation, COPD chronic obstructive pulmonary disease
  2. aSD = standardized difference (SD is defined as the difference in sample means or proportions divided by standard error; reported as 100*|actual standardize difference|. Standardize differences >|10| are considered significant
  3. bClinical stage: anatomic Extent of the disease based on the clinical T, N and M element
  4. cRisk Categories: Low risk (T1-T2A, PSA level ≤ 10 ng/mL, and Gleason score ≤ 6) and intermediate-risk (T1 or T2, PSA level > 10 and ≤ 20 ng/mL, and Gleason score = 7)